A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners
โ Scribed by Jean M. Donnelly; Alice B. Kornblith; Stewart Fleishman; Enid Zuckerman; George Raptis; Clifford A. Hudis; Nicola Hamilton; David Payne; Mary Jane Massie; Larry Norton; Jimmie C. Holland
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 92 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1057-9249
No coin nor oath required. For personal study only.
โฆ Synopsis
A single-arm pilot study explored the feasibility of adapting in Interpersonal Psychotherapy (IPT) by telephone to reduce psychological distress and to enhance coping during cancer treatment. Therapy focuses on role transitions, interpersonal conflicts, and grief precipitated by cancer. Breast cancer patients receiving high-dose chemotherapy received weekly sessions with a psychologist throughout chemotherapy and for 1 month afterwards. Patients could invite one 'partner' to receive individual telephone IPT. Psychosocial functioning was assessed using standardized measures at study entry, after chemotherapy, and following telephone IPT. Accrual and participation supplied evidence of feasibility: 14 patients and 10 partners were recruited, 82.5% of those eligible. Patients had a mean of 16 sessions; partners had a mean of 11. Participants rated their satisfaction with the program between 'good' and 'excellent'. A test of the efficacy of telephone IPT requires a larger, randomized trial. In order to standardize the intervention, a treatment manual was developed. This study indicated the importance of outreach to family members as well as to cancer patients, intensive patient education about oncology treatment and the medical care setting, and psychosocial services that continue after cancer treatment has been completed.
๐ SIMILAR VOLUMES
Heat shock protein (HSP)-peptide complexes isolated from murine cancers elicit protective immunity and T lymphocytes specific for the cancer from which the HSPs are isolated. A pilot study was designed to test the feasibility, immunogenicity and toxicity of such treatment in cancer patients. Sixteen
## Background: African-american patients have been under-represented in oncology clinical trials. better understanding barriers to african-american participation may help increase the accrual of african-american patients onto clinical trials. ## Methods: Two hundred eighteen patients with maligna